Thursday 25 Apr 2024
By
main news image

SINGAPORE (Jan 9): German pharmaceutical giant Boehringer Ingelheim is acquiring assets and intellectual property from Singapore-based biotech company Enleofen Bio, in a step towards finding effective treatments for fibro-inflammatory diseases.

In a press release on Thursday, Enleofen says Boehringer Ingelheim has acquired worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform.

For each new product, Boehringer Ingelheim will pay Enleofen earnout payments of more than US$1 billion (S$1.35 billion) in upfront and success-based...(click on link for full story on theedgesingapore.com)

      Print
      Text Size
      Share